As a world leader in the immuno-oncology field, Dr. Zihai Li has long been at the forefront of cancer immunotherapy.

Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect ...

Are time commitments related to cancer care toxic? Depends on who you ask.The term “time toxicity” has become cancer jargon over the past few years, sparking research into how much time patients spend ...

Toxicity-related T-DXd discontinuation was 15%, closely aligning with DESTINY-Breast04 (16.2%), supporting feasibility of administration in community oncology despite higher real-world disease burden.

Researchers launch a public immune atlas of pancreatic cancer therapy responses, allowing the public to rapidly link pancreatic cancer immunotherapy trials to immune shifts and outcomes. Imagine ...

Cancer surgery does not spread tumours, experts say, debunking common myths that often delay treatment. Senior oncologist explains that specialised surgical oncologists remove tumours with proper ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...

AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...

The alternative medicine industry is expanding rapidly, fueled in large part by the surge of health-related content on social ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...